新型冠狀病毒

Moderna cuts sales forecast for Covid-19 vaccine

US biotech’s shares fall as it blames delays in international shipping and manufacturing glitches for downgrade

Moderna has downgraded the sales forecasts for its Covid-19 vaccine this year, blaming delays in international shipping and temporary issues related to manufacturing capacity.

The US biotech said on Thursday it expects product sales of $15bn to $18bn in 2021, down from an earlier estimate of $20bn in August. The company now expects to deliver 700m to 800m doses this year, compared to earlier estimates of between 800m to 1bn.

Moderna shares fell as much as 11 per cent in premarket trading after the disappointing guidance. Consensus estimates from analysts had forecast full-year sales of $19.8bn.

您已閱讀29%(599字),剩餘71%(1467字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×